Skip to main content
Equibles

GTS SECURITIES LLC

Broker-Dealer

Position in ALNY — Alnylam Pharmaceuticals, Inc.

CIK 1452765 NEW YORK, NY
Back to ALNY Full portfolio

Position in ALNY

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$437,095
+$89,020 QoQ
Shares Held
1,452
+38.0% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#497
of 786 holders
Holding Since
Sep 2023
10 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in ALNY Over Time

Shares Held

Position Value (USD)

Derivatives in ALNY

reported options exposure · as of Sep 30, 2024
CallValue
$7,480,816
CallShares
27,200
PutValue
$7,838,355
PutShares
28,500

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

GTS SECURITIES LLC holds $5,249,889 across 19 Biotechnology names. ALNY ranks #4 (8.3% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ARGX
Argenx SE
 1,164 $1,079,924
2 GMAB
Genmab A/S
 32,116 $882,226
3 VRTX
Vertex Pharmaceuticals Inc / Ma
 1,060 $526,533
4 ALNY
Alnylam Pharmaceuticals, Inc.
This page 		1,452 $437,095
5 TBPH
Theravance Biopharma, Inc.
 25,320 $430,440
6 TLX
Telix Pharmaceuticals Ltd
 35,537 $409,741
7 REGN
Regeneron Pharmaceuticals, Inc.
 626 $390,336
8 BHVN
Biohaven Ltd.
 16,988 $252,781

All Filings in ALNY

Export CSV
18 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $437,095 1,452
2026-03-31 $348,075 1,052
2025-12-31 $208,766 525
2025-06-30 $243,589 747
2024-12-31 $273,665 1,163
2024-09-30 $7,838,355 28,500
2024-09-30 $7,480,816 27,200
2024-09-30 $2,256,071 8,203
2024-06-30 $9,817,200 40,400
2024-06-30 $13,097,700 53,900
2024-06-30 $266,328 1,096
2024-03-31 $7,068,985 47,300
2024-03-31 $4,752,510 31,800
2023-12-31 $376,312 1,966
2023-12-31 $7,981,797 41,700
2023-12-31 $6,622,786 34,600
2023-09-30 $7,331,940 41,400
2023-09-30 $6,676,670 37,700